A Tiny Laser Probe May Help Extend Survival for Patients With Difficult Brain Tumors
For people diagnosed with glioblastoma, one of the most aggressive forms of brain cancer, treatment often begins with a race against time. The disease can grow rapidly through delicate regions of the brain, making complete removal difficult or impossible without risking severe neurological damage. The standard approach has traditionally involved open-skull surgery, followed by radiation and chemotherapy, but a large analysis led by researchers at Washington University School of Medicine in St. Louis suggests that a much less invasive technique may offer important advantages for selected patients. The study found that both the amount of tumor destroyed and the timing of treatment were strongly associated with survival after laser interstitial thermal therapy, or LITT.
The findings come from an analysis of 787 patients enrolled in the prospective, multicenter LAANTERN study, which followed people with tumors originating in the brain as well as cancers that had spread there from other parts of the body. Patients were monitored for as long as five years after receiving treatment with the NeuroBlate system, a laser-based surgical tool developed by Monteris Medical. Washington University School of Medicine led the study at Siteman Cancer Center and coordinated participation from 24 additional sites across the United States. The results were published Aug. 17 in the Journal of Clinical Oncology, offering one of the largest evaluations to date of clinical outcomes after laser ablation for brain tumors.
LITT is designed for tumors that are recurrent, deeply located, or otherwise considered difficult to reach safely through conventional surgery. Rather than opening a large section of the skull, neurosurgeons create a small hole and insert a narrow laser probe into the brain. The probe is guided through tissue using robotic assistance and real-time magnetic resonance imaging, allowing surgeons to follow its position and monitor the temperature of surrounding structures during the procedure. Once the probe reaches the tumor, laser energy produces controlled thermal injury. The heat destroys cancer cells in the targeted region while MRI thermography helps physicians limit exposure to nearby healthy brain tissue. The procedure usually requires only a tiny incision closed with a single stitch.
The new analysis indicates that the degree of tumor destruction is not merely a technical detail but a major determinant of outcome, particularly for patients with newly diagnosed glioblastoma. Among patients whose tumors could not be removed through open surgery or had returned after previous treatment, those who achieved at least 91% tumor ablation survived a median of 2.1 years from the time of diagnosis. That figure is significant because survival following standard open surgical resection is approximately 1.5 years in comparable clinical contexts. The researchers say the data raise the possibility that laser treatment could have a role earlier in the treatment pathway for some patients, rather than being reserved exclusively for tumors that recur or cannot be accessed through conventional surgery.
The percentage of tumor destroyed is measured through imaging and reflects how completely the heated treatment zone overlaps with the cancerous tissue. A higher ablation percentage generally means that fewer viable tumor cells remain within the targeted mass, although the technique cannot eliminate every microscopic cancer cell that may have migrated beyond the visible tumor. Glioblastoma is especially challenging because its cells infiltrate surrounding brain tissue in complex patterns. Even when a visible mass is removed, invisible extensions can remain and later drive recurrence. LITT therefore does not replace radiation, chemotherapy, or other therapies in most treatment plans; instead, it can provide a focal intervention in cases where a conventional operation would carry unacceptable risks.
The study also produced a clinically important finding involving brain metastases, tumors formed when cancer spreads from another organ to the brain. The analysis focused on patients whose metastatic tumors had previously been treated with radiation and later showed signs of recurrence or treatment-related changes. Patients appeared to benefit more when laser therapy was performed while the tumors were still small. This result challenges a common watch-and-wait strategy in which doctors follow patients through several rounds of imaging to confirm that a lesion is growing before intervening. According to the findings, delaying treatment until a metastatic tumor becomes larger may reduce the potential benefit of LITT, while earlier treatment may allow the laser’s thermal field to cover a greater proportion of the tumor with less risk to surrounding brain tissue.
The procedure’s potential value extends beyond survival. Conventional craniotomy requires surgeons to temporarily remove part of the skull, and recovery can involve substantial pain, swelling, neurological monitoring, and weeks away from normal activities. By contrast, the laser procedure uses a passage only a few millimeters wide. In the LAANTERN analysis, the average hospital stay was approximately 32 hours, and most patients avoided intensive care and hospital readmission. The researchers also reported that the treatment generally preserved day-to-day quality of life and was associated with a reduced need for anti-seizure medication compared with the period before surgery. These measures matter greatly for patients with terminal or recurrent cancer, for whom maintaining independence and time at home may be as important as extending survival.
WashU Medicine researchers Eric C. Leuthardt and Albert H. Kim were among the investigators involved in the analysis. Leuthardt, the study’s principal investigator and lead author, said the work identifies factors that can help physicians select patients most likely to benefit and determine when treatment may be most effective. The study builds on more than a decade of experience with laser neurosurgery at Barnes-Jewish Hospital, part of BJC HealthCare. In 2010, Leuthardt performed the nation’s first LITT procedure for a brain metastasis at the hospital after the NeuroBlate device received clearance from the U.S. Food and Drug Administration in 2009. The program’s development was supported by early investments in intraoperative MRI, a technology that allows surgeons to visualize tissue and treatment effects during the operation rather than relying solely on scans taken before or after surgery.
Although the results are encouraging, the analysis was observational and should not be interpreted as proof that LITT is superior to open surgery for every patient with glioblastoma or metastatic disease. Treatment decisions depend on tumor size, location, shape, biological characteristics, previous radiation and chemotherapy, neurological symptoms, and the patient’s overall health. The device manufacturer, Monteris Medical, funded the study, and several investigators reported financial relationships with the company or other medical-technology and pharmaceutical organizations. Even with those considerations, the size and prospective design of the LAANTERN cohort provide unusually detailed evidence about how technical success and treatment timing influence outcomes. The researchers’ central message is that a minimally invasive laser procedure may offer its greatest benefit when physicians achieve extensive ablation and intervene before tumors become too large or too difficult to treat.
For patients facing a diagnosis that can rapidly limit both lifespan and quality of life, the prospect of returning home roughly a day after brain surgery represents a striking change from the traditional image of cancer treatment. LITT cannot cure every brain tumor, and its long-term role will require further comparative studies, but the new findings suggest that precision, timing, and careful patient selection could transform how difficult tumors are managed. By combining real-time MRI guidance with controlled thermal ablation, neurosurgeons are developing an approach that reaches deep brain lesions through a narrow path while preserving as much healthy tissue as possible. The study’s results may help move laser therapy from a last-resort option toward a more deliberately timed component of multidisciplinary brain-cancer care.
Subject of Research: People with brain tumors, including glioblastoma and brain metastases.
Article Title: Laser interstitial thermal therapy for brain tumors: a prospective multicenter analysis of 787 patients from the LAANTERN study.
News Publication Date: 17-Aug-2026
Web References: https://medicine.wustl.edu/news/lasers-help-fight-deadly-brain-tumors/ ; https://neurosurgery.wustl.edu/people/eric-c-leuthardt-md/ ; https://neurosurgery.wustl.edu/people/albert-h-kim-md-phd/
References: Journal of Clinical Oncology; LAANTERN prospective multicenter study.
Keywords: glioblastoma, brain cancer, laser interstitial thermal therapy, LITT, NeuroBlate, brain tumors, brain metastases, laser ablation, neurosurgery, MRI-guided surgery, cancer treatment, tumor recurrence, survival, minimally invasive surgery
